查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球治疗药物监测 (TDM) 市场：按产品、技术、药物类别、治疗领域、检体和最终用户 - 预测（至 2029 年）
市场调查报告书
商品编码
1620872

全球治疗药物监测 (TDM) 市场：按产品、技术、药物类别、治疗领域、检体和最终用户 - 预测（至 2029 年）

Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti-Epileptic Drugs,Anti-Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 381 Pages | 订单完成后即时交付

价格

全球治疗药物监测 (TDM) 市场规模预计将从 2024 年的 23 亿美元增加到 2029 年的 34.4 亿美元，复合年增长率为 8.4%。

免疫测量技术的进步仍然是这一成长的主要驱动力，对该行业的发展轨迹产生了积极影响。这些技术旨在提高药物监测的准确性、速度和特异性，包括增强化学冷光、ELISA 和萤光增强。同时，医疗专业人员越来越意识到TDM在改善治疗结果方面的重要性，从而将TDM引入临床实践。教育和培训工作正在提高临床医生对 TDM 好处的了解，并促进其在日常实践中的实施。总的来说，这些因素正在影响动态成长的市场环境。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
单元 美元
部分 产品、技术、药物类别、治疗领域、检体、最终用户、地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲、海湾合作委员会国家

“按产品划分，消耗品领域预计在预测期内将以最高的复合年增长率增长。”

在治疗药物监测（TDM）中，消耗品领域的复合年增长率最高。试剂、检测试剂套件和校准品等消耗品在 TDM 市场上备受追捧，因为它们对于癌症、心血管疾病和神经系统疾病等慢性但治疗复杂的疾病的治疗药物的常规监测至关重要。的角色。对个人化治疗的日益关注和对准确药物水平评估的需求导致对高品质耗材的需求增加。此外，花钱购买实验室和医院製造的先进 TDM 系统可能会增加对相关产品的需求，从而支持市场扩张。

“从检体来看，在预测期内，血液部分预计将占据最大的市场份额。”

血液是 TDM 最常用的检体，并且由于其能够准确、直接测量血浆和血清中的药物浓度而成为市场领导者。已製定血液采集和处理通讯协定，以确保可靠性和一致性。它还与免疫测量和 LC-MS/MS 等最尖端科技相容，可准确定量药物，满足治疗监测的最新需求。它还得到支持基于血液的 TDM 的监管指南和临床实践的支持。事实证明，它在药物动力学监测方面有利于剂量优化和改善治疗结果，所有这些都利于其在临床实践中的采用。

“美国将以北美药物监测市场最高复合年增长率增长。”

在美国，心血管疾病、糖尿病、神经系统疾病和癌症等慢性疾病的盛行率不断增加，推动了对 TDM 的需求。其中一些疾病需要加强监测，透过采取措施减少不利事件来优化治疗效果，这就是 TDM 技术采用步伐不断加快的原因。此外，该国的医疗保健框架完善且发达，拥有大量的医院、实验室和诊断中心，这进一步支持了先进端的整合。此外，在众多製药和生物技术公司的支持下，TDM 技术的不断创新确保了监测工具的可用性和先进性。所有这些因素共同推动了美国TDM市场的快速成长。

本报告研究和分析了全球治疗药物监测 (TDM) 市场，提供了包括关键驱动因素和限制因素、竞争格局和未来趋势等资讯。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

  • 治疗药物监测 (TDM) 市场概述
  • 按药物类别和国家分類的亚太地区治疗药物监测 (TDM)市场占有率（2023 年）
  • 治疗药物监测（TDM）市场：依主要国家分类
  • 治疗药物监测（TDM）市场：区域组成（2024-2029）
  • 治疗药物监测 (TDM) 市场：发展中市场与已开发市场

第五章市场概况

  • 介绍
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 价格分析
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 监管环境
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东
    • 非洲
  • 贸易分析
  • 专利分析
  • 主要会议和活动（2025/2026）
  • 影响客户业务的趋势/干扰
  • 技术分析
    • 主要技术
    • 互补技术
    • 邻近技术
  • 波特五力分析
  • 主要相关利益者和采购标准
  • 投资金筹措场景
  • 生成式人工智慧对治疗药物监测 (TDM) 市场的影响

第六章 治疗药物监测 (TDM) 市场：副产品

  • 介绍
  • 消耗品
  • 装置
    • 免疫分析仪
    • 层析法/MS检测器
    • 临床生化分析仪

第七章 治疗药物监测 (TDM) 市场：依技术分类

  • 介绍
  • 免疫测量
    • ELISA
    • 化学冷光免疫测量
    • 萤光免疫测量
    • 比色免疫测量
    • 其他免疫检测
  • 层析法-MS
    • 液相层析法-质谱法
    • 气相层析法质谱法
  • 其他技术

第八章 治疗药物监测 (TDM) 市场：依药物类别

  • 介绍
  • 抗癫痫药
  • 抗心律不整药物
  • 免疫抑制药物
  • 抗生素
  • 支气管扩张剂
  • 精神药物
  • 其他药品

第九章 治疗药物监测 (TDM) 市场：依治疗领域

  • 介绍
  • 神经系统疾病
  • 心臟病
  • 感染疾病
  • 瘤
  • 其他治疗领域

第 10 章 治疗药物监测 (TDM) 市场：依检体

  • 介绍
  • 血
  • 唾液
  • 其他检体

第 11 章 治疗药物监测 (TDM) 市场：依最终使用者分类

  • 介绍
  • 医院实验室
  • 商业/私人实验室
  • 其他最终用户

第十二章 治疗药物监测 (TDM) 市场：按地区

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
  • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
  • 亚太宏观经济展望
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 其他亚太地区
  • 拉丁美洲
  • 中东/非洲
  • 海湾合作委员会国家

第十三章竞争格局

  • 概述
  • 优势
  • 主要企业采取的策略
  • 收益分析
  • 市场占有率分析
  • 公司评估矩阵：主要企业
  • 公司评估矩阵：Start-Ups/中小企业
  • 公司评价及财务指标
  • 产品/品牌比较
  • 竞争场景

第十四章 公司简介

  • 主要企业
    • ABBOTT
    • THERMO FISHER SCIENTIFIC INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • SIEMENS HEALTHINEERS AG
    • DANAHER CORPORATION
    • BIO-RAD LABORATORIES, INC.
    • BIOMERIEUX SA
    • BIOSYNEX SA
    • GRIFOLS, SA
    • EXAGEN INC.
    • ARK DIAGNOSTICS, INC.
    • R-BIOPHARM AG
    • RANDOX LABORATORIES LTD.
  • 其他公司
    • APDIA GROUP
    • BBI SOLUTIONS
    • EAGLE BIOSCIENCES, INC.
    • JASEM LABORATORY SYSTEMS AND SOLUTIONS
    • AALTO SCIENTIFIC, LTD.
    • IMMUNDIAGNOSTIK AG
    • UTAK
    • SEKISUI MEDICAL CO., LTD.
    • DIASYSTEM SCANDINAVIA AB
    • CAMBRIDGE LIFE SCIENCES LIMITED
    • CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
    • BUHLMANN LABORATORIES AG
    • SJK GLOBAL, LLC
    • EPITOPE DIAGNOSTICS, INC.
    • QED BIOSCIENCE INC.
    • BODITECH MED INC.
    • IMMUNODIAGNOSTIC SYSTEMS

第十五章附录

Product Code: MD 4185

It is anticipated that the therapeutic drug monitoring market will grow from USD 2.30 billion in 2024 to USD 3.44 billion by 2029, with a steady compound annual growth rate (CAGR) of 8.4%. Advancements in immunoassay techniques remain a key driver of this growth, influencing the sector's trajectory in a positive manner. These techniques aim to improve the accuracy, speed, and specificity of medication monitoring, including enhanced chemiluminescence, ELISA, and fluorescence enhancement. In the meantime, healthcare professionals are becoming more aware of the significance of TDM in improving therapeutic outcomes, leading to its incorporation into clinical settings. Education and training initiatives have raised clinicians' understanding of the advantages of TDM, making it easier for the technology to be implemented in everyday patient care. Collaboratively, these elements are influencing a dynamic and growing market environment.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Product, Technology, Drug Class, Therapeutic Area, Specimen, End User, and Region
Regions coveredNorth America, Europe, APAC, Latin America, Middle East & Africa, and GCC Countries.

"Consumables segment is expected to grow at the highest CAGR during the forecast period, by product."

The consumables segment holds the highest CAGR in the therapeutic drug monitoring. Consumables such as reagents, assay kits, and calibrators create a very important part in the TDM market as they are integral in routine monitoring of drugs for chronic but complex-to-cure conditions such as cancer, cardiovascular, and neurological disorders. Demand for high-quality consumables is growing as a result of the increased focus on customized therapy and the need for precise medication level evaluation. Additionally, spending money on advanced TDM systems produced by labs and hospitals would raise demand for its related goods, which would support market expansion.

"Blood segment is expected to hold the largest share of TDM market during the forecast period, by specimen."

Blood, as it is the most used specimen for TDM, fuels the market owing to its capability to provide precise and direct measurement of drug concentrations in plasma or serum. Well-established protocols in the collection and processing of blood ensure that it is reliable and consistent, while its wide clinical acceptance is well established. It is compatible with the most advanced technologies, including immunoassays and LC-MS/MS, by which drugs can be accurately quantified, meeting modern demands in therapeutic monitoring. Besides, this is supported by regulatory guidelines and clinical practices, which favor blood-based TDM; it has proved its merit in monitoring pharmacokinetics for the optimization of dose , which improves therapeutic outcomes, all combining to favor its adoption in a clinical setting.

"US to grow at the highest CAGR for North America therapeutic drug monitoring market"

The increasing prevalence in the US of chronic diseases of a cardiovascular nature, diabetes, neurological disorders, and cancer, among many others, significantly fuels this demand for TDM. Several of these disorders require thorough monitoring for the optimization of their treatment efficacy by taking measures to reduce adverse events, hence increasing the pace of adoption of TDM technologies. The well-established and well-developed healthcare framework of the country involves large numbers of hospitals, laboratories, and diagnostic centers, which further fortifies the integration of advanced end. Besides, continuous innovation in TDM technologies, supported by the presence of numerous pharmaceutical and biotech companies, ensures availability and advances in monitoring tools. These are all factors combined to spur the rapid growth of the TDM market in the US.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the therapeutic drug monitoringmarketplace.

  • By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
  • By Designation: C-level Executives - 30%, Directors - 34%, and Others - 36%
  • By Region: North America- 40%, Europe - 25%, Asia Pacific- 19%, Latin America- 8%, Middle East & Africa- 6% and GCC Countries- 2%

The companies included in Therapeutic Drug Monitoring market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK), apDia Group (Belgium), BBI Solutions (UK), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), UTAK (US), Sekisui Medical Co., Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), BUHLMANN Laboratories AG (Switzerland), SJK Global, LLC (US), Epitope Diagnostics, Inc. (US), QED Bioscience Inc. (US), Boditech Med Inc. (South Korea), and Immunodiagnostic Systems (UK).

Research Coverage

This research report categorizes the therapeutic drug monitoring market by product (Equipment, and Consumables), by technology (Immunoassays, Chromatography-MS, and Other Technologies), by Drug Class (Anti-Epileptic Drugs, Anti-Arrhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Bronchodilator Drugs, Psychoactive Drugs, and Other Drug Classes), by Therapeutic Area (Neurological Disorders , Cardiology, Infectious Diseases, Oncology, Other Therapeutic Areas), by Specimen (Blood, Saliva, and other samples), by End User (Hospital Laboratories, Commercial & Private Laboratories, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Gountries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the therapeutic drug monitoring market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the therapeutic drug monitoring market. Competitive analysis of upcoming startups in the therapeutic drug monitoring market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall therapeutic drug monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Importance of therapeutic drug monitoring in organ transplant procedures, Use of therapeutic drug monitoring across various therapeutic fields, Increasing preferences for precision medicine, Growing focus on R&D related to therapeutic drug monitoring, Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, Increase in prevalence of Epilepsy, Rising prevalence of cancer to drive adoption of Therapeutic Drug Monitoring in Oncology Treatments), restraints (High capital investments, Reluctance of small hospitals to offer therapeutic drug monitoring services), opportunities (Significant opportunities in BRICS countries, Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring, Integration of AI and machine learning), and challenges (Alternatives to conventional therapeutic drug monitoring, Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries, Shortage of skilled professionals) influencing the growth of the therapeutic drug monitoring market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the therapeutic drug monitoring market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the therapeutic drug monitoring market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the therapeutic drug monitoring market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK)) among others in therapeutic drug monitoring market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
      • 2.2.1.2 Approach 2: Lab-based analysis
      • 2.2.1.3 Approach 3: Drug class-based analysis
      • 2.2.1.4 Approach 4: Presentations of companies and primary interviews
      • 2.2.1.5 Growth forecast
      • 2.2.1.6 CAGR projections
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ASSESSMENT
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 STUDY LIMITATIONS
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE, BY DRUG CLASS AND COUNTRY (2023)
  • 4.3 THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY
  • 4.4 THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024-2029
  • 4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Importance of therapeutic drug monitoring in organ transplant procedures
      • 5.2.1.2 Use of therapeutic drug monitoring across various therapeutic fields
      • 5.2.1.3 Increasing preference for precision medicine
      • 5.2.1.4 Growing focus on R&D related to therapeutic drug monitoring
      • 5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
      • 5.2.1.6 Increasing prevalence of epilepsy
      • 5.2.1.7 Rising prevalence of cancer
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investments
      • 5.2.2.2 Reluctance of small hospitals to offer therapeutic drug monitoring services
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Significant opportunities in BRICS countries
      • 5.2.3.2 Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring
      • 5.2.3.3 Integration of AI and machine learning
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Alternatives to conventional therapeutic drug monitoring
      • 5.2.4.2 Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries
      • 5.2.4.3 Shortage of skilled professionals
  • 5.3 PRICING ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 REGULATORY LANDSCAPE
    • 5.7.1 NORTH AMERICA
      • 5.7.1.1 US
      • 5.7.1.2 Canada
    • 5.7.2 EUROPE
    • 5.7.3 ASIA PACIFIC
      • 5.7.3.1 China
      • 5.7.3.2 Japan
      • 5.7.3.3 India
    • 5.7.4 LATIN AMERICA
    • 5.7.5 MIDDLE EAST
    • 5.7.6 AFRICA
  • 5.8 TRADE ANALYSIS
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026
  • 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 KEY TECHNOLOGY
      • 5.12.1.1 Enzyme-linked immunosorbent assay
    • 5.12.2 COMPLEMENTARY TECHNOLOGY
      • 5.12.2.1 Liquid chromatography-mass spectrometry
    • 5.12.3 ADJACENT TECHNOLOGY
      • 5.12.3.1 Electrophoresis
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 THREAT OF NEW ENTRANTS
    • 5.13.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.13.3 BARGAINING POWER OF BUYERS
    • 5.13.4 BARGAINING POWER OF SUPPLIERS
    • 5.13.5 THREAT OF SUBSTITUTES
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
  • 5.15 INVESTMENT AND FUNDING SCENARIO
  • 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC DRUG MONITORING MARKET

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    • 6.2.1 REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET
  • 6.3 EQUIPMENT
    • 6.3.1 IMMUNOASSAY ANALYZERS
      • 6.3.1.1 High efficiency to drive adoption
    • 6.3.2 CHROMATOGRAPHY & MS DETECTORS
      • 6.3.2.1 Technological advancements to propel growth
    • 6.3.3 CLINICAL CHEMISTRY ANALYZERS
      • 6.3.3.1 Increasing incidence of chronic and complex diseases to drive market

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 IMMUNOASSAYS
    • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
      • 7.2.1.1 Accurate measurement of target-specific proteins to drive market
    • 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
      • 7.2.2.1 Rapid detection time and good specificity to support growth
    • 7.2.3 FLUORESCENCE IMMUNOASSAYS
      • 7.2.3.1 High operability and better sensitivity of FIAs to drive market
    • 7.2.4 COLORIMETRIC IMMUNOASSAYS
      • 7.2.4.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
    • 7.2.5 OTHER IMMUNOASSAYS
  • 7.3 CHROMATOGRAPHY-MS
    • 7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
      • 7.3.1.1 High accuracy to drive demand for LC-MS
    • 7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
      • 7.3.2.1 Drawbacks of GC-MS to challenge market growth
  • 7.4 OTHER TECHNOLOGIES

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

  • 8.1 INTRODUCTION
  • 8.2 ANTIEPILEPTIC DRUGS
    • 8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
  • 8.3 ANTIARRHYTHMIC DRUGS
    • 8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
  • 8.4 IMMUNOSUPPRESSANT DRUGS
    • 8.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES TO DRIVE MARKET
  • 8.5 ANTIBIOTIC DRUGS
    • 8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND
  • 8.6 BRONCHODILATOR DRUGS
    • 8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
  • 8.7 PSYCHOACTIVE DRUGS
    • 8.7.1 RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
  • 8.8 OTHER DRUGS

9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
  • 9.2 NEUROLOGICAL DISORDERS
    • 9.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
  • 9.3 CARDIOLOGY
    • 9.3.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
  • 9.4 INFECTIOUS DISEASES
    • 9.4.1 INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND
  • 9.5 ONCOLOGY
    • 9.5.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET
  • 9.6 OTHER THERAPEUTIC AREAS

10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN

  • 10.1 INTRODUCTION
  • 10.2 BLOOD
    • 10.2.1 INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET
  • 10.3 SALIVA
    • 10.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
  • 10.4 OTHER SAMPLES

11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITAL LABORATORIES
    • 11.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO DRIVE MARKET
  • 11.3 COMMERCIAL & PRIVATE LABORATORIES
    • 11.3.1 EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
  • 11.4 OTHER END USERS

12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
    • 12.2.2 US
      • 12.2.2.1 Increasing awareness regarding precision medicine to propel market
    • 12.2.3 CANADA
      • 12.2.3.1 Availability of funding for research to offer growth opportunities
  • 12.3 EUROPE
  • 12.4 EUROPE: MACROECONOMIC OUTLOOK
    • 12.4.1 GERMANY
      • 12.4.1.1 Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth
    • 12.4.2 UK
      • 12.4.2.1 Increasing cases of chronic diseases to drive market
    • 12.4.3 FRANCE
      • 12.4.3.1 Rising awareness of benefits of therapeutic drug monitoring to accelerate demand
    • 12.4.4 ITALY
      • 12.4.4.1 Rising incidence of cancer to drive demand
    • 12.4.5 SPAIN
      • 12.4.5.1 Adoption of technologically advanced immunoassays to boost market
    • 12.4.6 REST OF EUROPE
  • 12.5 ASIA PACIFIC
  • 12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK
    • 12.6.1 JAPAN
      • 12.6.1.1 High prevalence of chronic diseases and advanced healthcare infrastructure to drive market
    • 12.6.2 CHINA
      • 12.6.2.1 Rising number of organ transplants to boost market
    • 12.6.3 INDIA
      • 12.6.3.1 Rising incidence of cancer to propel market
    • 12.6.4 AUSTRALIA
      • 12.6.4.1 High healthcare expenditure and favorable government initiatives to propel market
    • 12.6.5 REST OF ASIA PACIFIC
  • 12.7 LATIN AMERICA
    • 12.7.1 INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
    • 12.7.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 12.8 MIDDLE EAST & AFRICA
    • 12.8.1 INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET
    • 12.8.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 12.9 GCC COUNTRIES
    • 12.9.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
    • 12.9.2 GCC COUNTRIES: MACROECONOMIC OUTLOOK

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 RIGHT TO WIN
  • 13.3 STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.4 REVENUE ANALYSIS
  • 13.5 MARKET SHARE ANALYSIS
  • 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 13.6.1 STARS
    • 13.6.2 EMERGING LEADERS
    • 13.6.3 PERVASIVE PLAYERS
    • 13.6.4 PARTICIPANTS
    • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 13.6.5.1 Company footprint
      • 13.6.5.2 Region footprint
      • 13.6.5.3 Product footprint
      • 13.6.5.4 Technology footprint
      • 13.6.5.5 End-user footprint
  • 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES
    • 13.7.1 PROGRESSIVE COMPANIES
    • 13.7.2 RESPONSIVE COMPANIES
    • 13.7.3 DYNAMIC COMPANIES
    • 13.7.4 STARTING BLOCKS
    • 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
      • 13.7.5.1 Detailed list of key startups/SMEs
  • 13.8 COMPANY VALUATION & FINANCIAL METRICS
    • 13.8.1 FINANCIAL METRICS
    • 13.8.2 COMPANY VALUATION
  • 13.9 PRODUCT/BRAND COMPARISON
  • 13.10 COMPETITIVE SCENARIO
    • 13.10.1 PRODUCT LAUNCHES
    • 13.10.2 DEALS
    • 13.10.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 ABBOTT
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 MnM view
        • 14.1.1.3.1 Key strengths
        • 14.1.1.3.2 Strategic choices
        • 14.1.1.3.3 Weaknesses and competitive threats
    • 14.1.2 THERMO FISHER SCIENTIFIC INC.
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches
        • 14.1.2.3.2 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 F. HOFFMANN-LA ROCHE LTD.
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches
        • 14.1.3.3.2 Deals
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 SIEMENS HEALTHINEERS AG
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 DANAHER CORPORATION
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches
        • 14.1.5.3.2 Deals
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 BIO-RAD LABORATORIES, INC.
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches
        • 14.1.6.3.2 Deals
    • 14.1.7 BIOMERIEUX SA
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
    • 14.1.8 BIOSYNEX SA
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches
        • 14.1.8.3.2 Deals
    • 14.1.9 GRIFOLS, S.A.
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Deals
    • 14.1.10 EXAGEN INC.
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Deals
    • 14.1.11 ARK DIAGNOSTICS, INC.
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products offered
    • 14.1.12 R-BIOPHARM AG
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Product launches
    • 14.1.13 RANDOX LABORATORIES LTD.
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 APDIA GROUP
    • 14.2.2 BBI SOLUTIONS
    • 14.2.3 EAGLE BIOSCIENCES, INC.
    • 14.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
    • 14.2.5 AALTO SCIENTIFIC, LTD.
    • 14.2.6 IMMUNDIAGNOSTIK AG
    • 14.2.7 UTAK
    • 14.2.8 SEKISUI MEDICAL CO., LTD.
    • 14.2.9 DIASYSTEM SCANDINAVIA AB
    • 14.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
    • 14.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
    • 14.2.12 BUHLMANN LABORATORIES AG
    • 14.2.13 SJK GLOBAL, LLC
    • 14.2.14 EPITOPE DIAGNOSTICS, INC.
    • 14.2.15 QED BIOSCIENCE INC.
    • 14.2.16 BODITECH MED INC.
    • 14.2.17 IMMUNODIAGNOSTIC SYSTEMS

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 RISK ASSESSMENT: THERAPEUTIC DRUG MONITORING MARKET
  • TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
  • TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
  • TABLE 4 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY TYPE
  • TABLE 5 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY KEY PLAYER, 2022-2024
  • TABLE 6 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY KEY REGION
  • TABLE 7 THERAPEUTIC DRUG MONITORING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 IMPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 14 LIST OF CONFERENCES AND EVENTS, 2025-2026
  • TABLE 15 THERAPEUTIC DRUG MONITORING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
  • TABLE 17 KEY BUYING CRITERIA FOR END USERS
  • TABLE 18 AI APPLICATIONS IN THERAPEUTIC DRUG MONITORING
  • TABLE 19 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 20 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 21 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 22 EUROPE: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 23 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
  • TABLE 25 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 26 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 27 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 31 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY, 2020-2024
  • TABLE 35 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 44 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 45 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 50 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 EXAMPLES OF CLIA SYSTEMS
  • TABLE 54 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS
  • TABLE 55 THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
  • TABLE 60 THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 61 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 73 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 85 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 90 DOSAGE GUIDELINES FOR NEW ANTIEPILEPTIC DRUGS IN ADOLESCENTS AND ADULTS
  • TABLE 91 THERAPEUTIC DRUG MONITORING: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS
  • TABLE 92 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 CLASSIFICATION OF ANTIARRHYTHMIC THERAPIES
  • TABLE 97 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 99 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 COMMONLY USED IMMUNOSUPPRESSANT DRUGS IN ORGAN TRANSPLANTS
  • TABLE 102 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 103 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 EXAMPLES OF ANTIBIOTIC DRUGS
  • TABLE 107 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIAL LEVELS IN BIOFLUIDS
  • TABLE 108 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 109 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 EXAMPLES OF BRONCHODILATOR DRUGS
  • TABLE 113 THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 EXAMPLES OF PSYCHOACTIVE DRUGS
  • TABLE 118 THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 119 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 EXAMPLES OF OTHER DRUGS
  • TABLE 123 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 124 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 128 PREVALENCE OF NEUROLOGICAL DISORDERS
  • TABLE 129 THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 134 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 138 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 141 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2040 (MILLION)
  • TABLE 142 THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 143 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 146 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 147 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 148 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 150 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 151 THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 152 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 153 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 156 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 157 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 158 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 159 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 160 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 163 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 164 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 165 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 166 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 168 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 169 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 170 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 172 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 174 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 177 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 178 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 179 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 180 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 182 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 183 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 184 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 185 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 186 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 187 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 188 FDA NOVEL DRUG THERAPY APPROVALS FOR 2023
  • TABLE 189 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
  • TABLE 190 US: NUMBER OF LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY TESTS, 2022-2029 (MILLION)
  • TABLE 191 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 192 US: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 193 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 194 US: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 195 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 197 US: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 198 US: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 199 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 200 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 201 CANADA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 202 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 203 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 204 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 205 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 206 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 207 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 208 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 209 EUROPE: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 210 EUROPE: KEY MACROINDICATORS
  • TABLE 211 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 212 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 213 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 214 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 215 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 216 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 217 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 218 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 219 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 220 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 221 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 222 GERMANY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 223 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 224 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 225 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 226 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 227 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 228 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 229 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 230 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 231 UK: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 232 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 233 UK: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 234 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 235 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 236 UK: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 237 UK: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 238 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 239 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 240 FRANCE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 241 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 242 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 243 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 244 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 245 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 246 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 247 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 248 ITALY: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 249 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 250 ITALY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 251 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 252 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 254 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 255 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 256 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 257 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 258 SPAIN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 259 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 260 SPAIN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 261 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 262 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 263 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 264 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 265 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 266 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 267 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 268 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 269 REST OF EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 270 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 271 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 272 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 273 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 274 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 275 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 276 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 278 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 280 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 282 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 283 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 284 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 285 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 286 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 288 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 289 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 290 JAPAN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 291 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 292 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 293 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 295 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 296 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 297 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 298 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 299 CHINA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 301 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 302 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 303 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 304 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 305 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 306 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 307 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 308 INDIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 309 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 310 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 311 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 312 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 313 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 314 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 315 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 316 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 317 AUSTRALIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 318 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 319 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 320 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 321 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 322 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 323 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 324 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 325 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 326 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 327 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 328 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 329 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 330 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 331 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 332 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 333 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 334 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 335 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 336 LATIN AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 337 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 338 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 339 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 340 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 341 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 342 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 343 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 344 MIDDLE EAST & AFRICA: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045
  • TABLE 345 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 346 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 347 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 348 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 349 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 350 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 352 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 355 GCC COUNTRIES: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045
  • TABLE 356 GCC COUNTRIES: KEY MACROINDICATORS
  • TABLE 357 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 358 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 359 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 360 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 361 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 362 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
  • TABLE 363 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
  • TABLE 364 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • TABLE 365 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 366 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021-NOVEMBER 2024
  • TABLE 367 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
  • TABLE 368 THERAPEUTIC DRUG MONITORING MARKET: REGION FOOTPRINT
  • TABLE 369 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT FOOTPRINT
  • TABLE 370 THERAPEUTIC DRUG MONITORING MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 371 THERAPEUTIC DRUG MONITORING MARKET: END-USER FOOTPRINT
  • TABLE 372 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 373 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 374 THERAPEUTIC DRUG MONITORING MARKET: DEALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 375 THERAPEUTIC DRUG MONITORING MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 376 ABBOTT: COMPANY OVERVIEW
  • TABLE 377 ABBOTT: PRODUCTS OFFERED
  • TABLE 378 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 379 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 380 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 381 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 382 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 383 CURRENCY CONVERSION FOR F. HOFFMANN-LA ROCHE LTD.
  • TABLE 384 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 385 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
  • TABLE 386 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 387 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 388 CURRENCY CONVERSION FOR SIEMENS HEALTHINEERS AG
  • TABLE 389 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 390 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
  • TABLE 391 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 392 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 393 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 394 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 395 DANAHER CORPORATION: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 396 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 397 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 398 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
  • TABLE 399 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 400 BIOMERIEUX SA: COMPANY OVERVIEW
  • TABLE 401 CURRENCY CONVERSION FOR BIOMERIEUX SA
  • TABLE 402 BIOMERIEUX SA: PRODUCTS OFFERED
  • TABLE 403 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 404 CURRENCY CONVERSION FOR BIOSYNEX SA
  • TABLE 405 BIOSYNEX SA: PRODUCTS OFFERED
  • TABLE 406 BIOSYNEX SA: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 407 BIOSYNEX SA: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 408 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 409 GRIFOLS, S.A.: PRODUCTS OFFERED
  • TABLE 410 GRIFOLS, S.A.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 411 EXAGEN INC.: COMPANY OVERVIEW
  • TABLE 412 EXAGEN INC.: PRODUCTS OFFERED
  • TABLE 413 EXAGEN INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 414 ARK DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 415 ARK DIAGNOSTICS, INC.: PRODUCTS OFFERED
  • TABLE 416 R-BIOPHARM AG: COMPANY OVERVIEW
  • TABLE 417 R-BIOPHARM AG: PRODUCTS OFFERED
  • TABLE 418 R-BIOPHARM AG: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 419 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
  • TABLE 420 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED
  • TABLE 421 APDIA GROUP: COMPANY OVERVIEW
  • TABLE 422 BBI SOLUTIONS: COMPANY OVERVIEW
  • TABLE 423 EAGLE BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 424 JASEM LABORATORY SYSTEMS AND SOLUTIONS: COMPANY OVERVIEW
  • TABLE 425 AALTO SCIENTIFIC, LTD.: COMPANY OVERVIEW
  • TABLE 426 IMMUNDIAGNOSTIK AG: COMPANY OVERVIEW
  • TABLE 427 UTAK: COMPANY OVERVIEW
  • TABLE 428 SEKISUI MEDICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 429 DIASYSTEM SCANDINAVIA AB: COMPANY OVERVIEW
  • TABLE 430 CAMBRIDGE LIFE SCIENCES LIMITED: COMPANY OVERVIEW
  • TABLE 431 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY OVERVIEW
  • TABLE 432 BUHLMANN LABORATORIES AG: COMPANY OVERVIEW
  • TABLE 433 SJK GLOBAL, LLC: COMPANY OVERVIEW
  • TABLE 434 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 435 QED BIOSCIENCE INC.: COMPANY OVERVIEW
  • TABLE 436 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 437 IMMUNODIAGNOSTIC SYSTEMS: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION
  • FIGURE 2 THERAPEUTIC DRUG MONITORING MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 6 ESTIMATING GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 TOP-DOWN APPROACH
  • FIGURE 9 DATA TRIANGULATION
  • FIGURE 10 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 17 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE MARKET
  • FIGURE 18 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH FROM 2024 TO 2029
  • FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 22 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS, APRIL 1, 2020-MARCH 31, 2024
  • FIGURE 24 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015-2022
  • FIGURE 25 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING, 2015-2021
  • FIGURE 26 INCIDENCE OF DIABETES, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION)
  • FIGURE 27 NUMBER OF US ADULTS WITH ACTIVE EPILEPSY, BY AGE GROUP (THOUSAND)
  • FIGURE 28 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
  • FIGURE 29 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2014-2021
  • FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 31 DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • FIGURE 32 THERAPEUTIC DRUG MONITORING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 33 PATENT ANALYSIS FOR THERAPEUTIC DRUG MONITORING, JANUARY 2015-DECEMBER 2023
  • FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING
  • FIGURE 35 THERAPEUTIC DRUG MONITORING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
  • FIGURE 37 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 38 INVESTMENT AND FUNDING SCENARIO
  • FIGURE 39 US: PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2023
  • FIGURE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
  • FIGURE 41 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
  • FIGURE 42 THERAPEUTIC DRUG MONITORING MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD BILLION)
  • FIGURE 43 THERAPEUTIC DRUG MONITORING MARKET SHARE ANALYSIS, 2023
  • FIGURE 44 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 45 THERAPEUTIC DRUG MONITORING MARKET: COMPANY FOOTPRINT
  • FIGURE 46 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 47 EV/EBITDA OF KEY VENDORS
  • FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 49 THERAPEUTIC DRUG MONITORING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 54 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 56 BIOMERIEUX SA: COMPANY SNAPSHOT (2023)
  • FIGURE 57 BIOSYNEX SA: COMPANY SNAPSHOT (2023)
  • FIGURE 58 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 EXAGEN INC.: COMPANY SNAPSHOT (2023)